Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing engineered cell-based oncolytic virus therapies for cancer treatment. The company reached public markets through a business combination with First Light Acquisition Group (Nasdaq: FLAG), a blank-check company sponsored by First Light Capital Group that completed its initial public offering in 2021. An S-1/A registration amendment was filed on April 15, 2024, under accession number 0001493152-24-014529, reflecting continued compliance activity following the de-SPAC closing. Calidi operates within the biotechnology and oncology sector, advancing cell-loaded viral therapy candidates through clinical development. For complete filing history, sponsor details, and comprehensive SPAC transaction analytics, sign up for full data access on SpacDesk.